| WB | 1/500-1/1000 | Human,Mouse,Rat |
| IF | 1/20 | Human,Mouse,Rat |
| IHC | 1/50-1/100 | Human,Mouse,Rat |
| ICC | 1/50-1/200 | Human,Mouse,Rat |
| FCM | 1/50-1/100 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | P54; AIG6; FKBP51; FKBP54; PPIase; Ptg-10 |
| Entrez GeneID | 2289 |
| WB Predicted band size | Calculated MW: 51 kDa; Observed MW: 51 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Rat |
| Immunogen | A synthesized peptide derived from human FKBP51 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是3篇关于FKBP51抗体的参考文献摘要(虚构示例，仅供参考)：
1. **文献名称**：*FKBP51 Antibody-Based Detection in Alzheimer’s Disease Models*
**作者**：Jaeger S. et al.
**摘要**：研究报道了一种高特异性FKBP51抗体的开发，用于检测阿尔茨海默病小鼠脑组织中FKBP51的表达上调，并探讨其与Tau蛋白异常磷酸化的关联。
2. **文献名称**：*Role of FKBP51 in Cancer: Validation via Novel Monoclonal Antibody*
**作者**：Anthony T.M. et al.
**摘要**：通过新型单克隆抗体证实FKBP51在卵巢癌细胞中的高表达，并揭示其通过调控AKT信号通路促进化疗耐药性的机制。
3. **文献名称**：*FKBP51 Antibody Application in Metabolic Syndrome Studies*
**作者**：Hähle A. et al.
**摘要**：利用特异性FKBP51抗体发现其在肥胖患者脂肪组织中的异常表达，提示其可能通过炎症反应参与胰岛素抵抗的发生。
4. **文献名称**：*FKBP51 Antibody Cross-Reactivity Analysis in Mammalian Tissues*
**作者**：Jenei-Lanzl Z. et al.
**摘要**：评估了多种商业FKBP51抗体在人类及小鼠组织中的交叉反应性，为实验选择高特异性抗体提供了技术参考，并应用于类风湿性关节炎滑膜组织研究。
(注：以上文献为模拟内容，实际引用需查询真实数据库如PubMed。)
The FKBP51 antibody is a crucial tool for studying the FK506-binding protein 51 (FKBP51), a member of the immunophilin protein family. FKBP51. encoded by the *FKBP5* gene, acts as a molecular chaperone with peptidyl-prolyl isomerase activity, regulating protein folding and interactions. It plays a key role in stress response pathways by modulating glucocorticoid receptor (GR) sensitivity, impacting hormone signaling and cellular stress adaptation. Dysregulation of FKBP51 is linked to psychiatric disorders (e.g., depression, PTSD), metabolic syndromes, and neurodegenerative diseases, making it a therapeutic target of interest.
FKBP51 antibodies enable researchers to detect and quantify FKBP51 expression in tissues and cells via techniques like Western blotting, immunohistochemistry, and immunofluorescence. These antibodies help elucidate its subcellular localization, interaction partners (e.g., GR, HSP90), and functional roles in disease models. Specific monoclonal or polyclonal variants are validated for selectivity against FKBP51. minimizing cross-reactivity with homologous proteins like FKBP52. Recent studies utilize these antibodies to explore FKBP51 inhibition strategies, aiming to develop treatments for stress-related conditions or metabolic disorders. By facilitating mechanistic insights, FKBP51 antibodies remain pivotal in advancing both basic research and translational applications targeting this versatile chaperone protein.
×
